A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
Diseases of the Nervous System
What is the purpose of this trial?
The purpose of this study is to assess the efficacy, safety, and tolerability profile of CVL-865 as adjunctive treatment in participants with drug-resistant focal onset seizures.
- Ages18 years - 75 years
- Trial withCerevel Therapeutics, LLC
- Start Date07/25/2020
- End Date10/31/2022
- Last Updated06/19/2022
- Study HIC#2000027109